📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-03 17:27
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Amerise Biosciences Reports Rs 8.14 Lakh Net Loss in Q1 FY27 on Zero Revenue
Amerise Biosciences reported zero revenue from operations for the quarter ended June 30, 2026, a sharp decline from Rs 7.92 lakhs in the previous quarter. The company swung to a net loss of Rs 8.14 lakhs, compared to a profit of Rs 6.13 lakhs in the March 2026 quarter. Total expenses for the period stood at Rs 8.14 lakhs, primarily driven by 'Other expenses' of Rs 7.21 lakhs. The company's paid-up equity capital remains unchanged at Rs 660.69 lakhs.
Confidence: HIGH
What changedThe company transitioned from a small profit-making quarter in March 2026 to reporting zero revenue and a net loss in June 2026.
Why it mattersFor a micro-cap company with a net worth of approximately Rs 5 Cr, the lack of revenue and continued operational expenses pose a risk to capital erosion.
Revenue (Q1 FY27): Rs 0.00Net Loss (Q1 FY27): Rs 8.14 lakhsOther Expenses: Rs 7.21 lakhsPaid-up Equity Capital: Rs 660.69 lakhs
📅 Short termNegative sentiment is likely as the company failed to generate any operational income during the quarter.
📈 Long termLimited structural significance unless the company can establish a consistent and scalable revenue model beyond its current micro-scale operations.
⚠ Risk flags
- Zero operational revenue
- Small scale of operations
- Volatility in quarterly performance
Key Highlights
Revenue from operations dropped to Rs 0.00 in Q1 FY27 from Rs 7.92 lakhs in Q4 FY26.
Net loss for the quarter was Rs 8.14 lakhs compared to a profit of Rs 6.13 lakhs in the preceding quarter.
Other expenses accounted for 88.5% of total quarterly expenditure at Rs 7.21 lakhs.
Employee benefit expenses decreased to Rs 0.94 lakhs from Rs 1.45 lakhs in the previous quarter.
Basic and Diluted EPS turned negative at Rs (0.01) for the quarter.
👀 What to Watch
Investors should monitor the company's ability to resume revenue generation in upcoming quarters, as the current results indicate a total halt in operational income.
Amerise Biosciences Reports Zero Revenue and Rs 8.14 Lacs Net Loss in Q1 FY27
Amerise Biosciences Ltd reported a complete halt in revenue for the quarter ended June 30, 2026, recording Rs 0.00 in operations compared to Rs 7.92 lacs in the previous quarter. The company posted a net loss of Rs 8.14 lacs, a sharp reversal from the Rs 6.13 lacs profit recorded in Q4 FY26. Expenses were dominated by 'Other Expenses' at Rs 7.21 lacs, while employee benefit expenses stood at Rs 0.94 lacs. The company continues to operate with negative 'Other Equity' of Rs 121.10 lacs as of March 2026, indicating sustained financial pressure.
Confidence: HIGH
What changedThe company transitioned from a marginally profitable quarter with small revenue to a quarter with zero revenue and a net loss.
Why it mattersFor a micro-cap company with a net worth of only Rs 5 Cr and negative reserves, a total lack of revenue and continued losses pose a significant risk to business continuity.
Revenue (Q1 FY27): Rs 0.00Net Loss (Q1 FY27): Rs 8.14 lacsOther Expenses: Rs 7.21 lacsPaid-up Capital: Rs 660.69 lacsOther Equity (Mar 2026): Rs -121.10 lacs
📅 Short termThe stock is likely to face downward pressure due to the lack of operational income and the shift back into losses.
📈 Long termThe long-term outlook remains highly speculative given the extremely low scale of operations and negative reserves.
⚠ Risk flags
- Zero operational revenue
- Negative other equity/reserves
- Micro-cap liquidity risk
- High concentration of 'Other Expenses' without corresponding revenue
Key Highlights
Revenue from operations dropped to Rs 0.00 in Q1 FY27 from Rs 7.92 lacs in Q4 FY26.
Net loss for the quarter was Rs 8.14 lacs compared to a profit of Rs 6.13 lacs in the preceding quarter.
Other expenses accounted for 88.5% of total quarterly expenditure at Rs 7.21 lacs.
Paid-up equity share capital remains at Rs 660.69 lacs with a face value of Rs 1 per share.
Other Equity remains negative at Rs -121.10 lacs as per the last audited balance sheet.
👀 What to Watch
Investors should monitor the company's ability to resume revenue generation in the coming quarters and check for any management commentary regarding the cessation of operations this quarter.
Rs 8.14 Lakh Net Loss: Amerise Biosciences Reports Zero Revenue in Q1 FY27
Amerise Biosciences reported a net loss of Rs 8.14 Lakhs for the quarter ended June 30, 2026, a significant decline from a profit of Rs 6.13 Lakhs in the previous quarter (Q4 FY26). Revenue from operations fell to zero during the quarter, compared to Rs 7.92 Lakhs in the sequential quarter and Rs 6.37 Lakhs in the year-ago period. Total expenses for the quarter were Rs 8.14 Lakhs, primarily driven by 'Other expenses' of Rs 7.21 Lakhs. The company continues to operate at an extremely small scale with a total paid-up equity capital of Rs 6.61 Cr.
Confidence: HIGH
What changedThe company swung from a marginal profit to a net loss as its revenue from operations dropped to zero during the quarter.
Why it mattersFor a micro-cap company with a net worth of only Rs 5 Cr, a quarter with zero revenue and mounting losses indicates significant operational instability.
Revenue (Q1 FY27): Rs 0.00Net Loss (Q1 FY27): Rs 8.14 LakhsTotal Expenses (Q1 FY27): Rs 8.14 LakhsEquity Share Capital: Rs 660.69 Lakhs
📅 Short termThe stock may face negative pressure due to the reported loss and the absence of any operational revenue during the quarter.
📈 Long termLimited; the company's long-term viability depends on its ability to establish a consistent and scalable revenue model, which is currently absent.
⚠ Risk flags
- Zero operational revenue for the quarter
- High other expenses relative to zero income
- Micro-cap liquidity and scale risks
Key Highlights
Revenue from operations dropped to Rs 0.00 in Q1 FY27 from Rs 7.92 Lakhs in Q4 FY26.
Net loss for the quarter stood at Rs 8.14 Lakhs compared to a profit of Rs 6.13 Lakhs in the preceding quarter.
Other expenses accounted for the majority of the quarterly spend at Rs 7.21 Lakhs.
Employee benefit expenses were recorded at Rs 0.94 Lakhs for the quarter.
Paid-up equity share capital remains unchanged at Rs 660.69 Lakhs (Face Value Rs 1).
👀 What to Watch
Investors should monitor subsequent quarterly filings to see if the company can resume revenue generation, as the current quarter shows a complete halt in operations.
